

Access to an *anti*,*syn*-1,5,7-Triol via Configuration-Encoded 1,5-Polyol Synthesis: The C15–C25 Fragment of Tetrafibricin

Ryan M. Friedrich, Gregory K. Friestad*^[a]

Abstract: A configuration-encoded strategy provides unambiguous stereocontrol in an efficient synthesis of 1,5-polyols. To access the *anti*,*syn*-1,5,7-triol moiety in the C15–C25 fragment of tetrafibricin, a fibrinogen receptor antagonist, a strategy is introduced which sequences the 1,5-polyol synthesis with selective desilylation and diastereoselective intramolecular conjugate addition. For tetrafibricin, assembly of the C15–C25 *anti*-1,5-diol in five steps is followed by the conjugate addition to introduce a *syn*-1,3-diol, completing the *anti*,*syn*-1,5,7-triol and providing the functionality and stereochemistry required for tetrafibricin synthesis.

Introduction

Tetrafibricin (Figure 1), isolated from *Streptomyces neyagawaensis* NR0577 in 1993, is a potent nonpeptidic fibrinogen receptor antagonist ($IC_{50} = 46$ nM) that inhibits platelet aggregation by blocking GPIIb/IIIa receptors, making it a potential drug candidate for arterial thrombotic diseases.^[1] Since its stereochemical structure elucidation in 2003 using an NMR database approach,^[2] strategies toward the synthesis of tetrafibricin have generated considerable interest; the laboratories of Cossy,^[3] Curran,^[4] and Krische^[5] each reported preparations of various fragments of the natural product. Studies from the Roush group^[6] led to a synthesis of *N*-acetyl dihydrotetrafibricin methyl ester.^[6a]

We previously reported an efficient route to a C27-C40 fragment of tetrafibricin7 which addressed the problem of stereocontrolled 1,5-polyol synthesis.^[8] Although many methods have been devised for the synthesis and stereochemical assignment of 1,3-diol motifs,^[9] few are applicable to the more distant 1,5 stereochemical relationships.^[8] We introduced a strategy to rapidly assemble any of the relative configurations of chiral 1,5-polyols with unambiguous stereocontrol (Figure 2a). The alcohol configurations are encoded within enantiopure α silyloxy-y-sulfononitrile building blocks which may be coupled iteratively via Julia-Kocienski olefinations; the nitrile serves as a masked aldehyde, revealed by hydride reduction.^[7] In contrast to other approaches to 1,5-diol synthesis, this iterative coupling sequence employs commercial reagents commonly on hand in most synthetic chemistry labs (KHMDS and DIBAL-H) making it practical to adopt. The configuration-encoded strategy avoids the difficulties of both control and assignment of 1,5-

 [a] R. M. Friedrich, G.K. Friestad Department of Chemistry University of Iowa
 Iowa City, Iowa, 52242, USA
 E-mail: gregory-friestad@uiowa.edu

Supporting information for this article is given via a link at the end of the document.

stereochemical relationships at each coupling event, contributing to the efficiency of our route to the C27–C40 fragment of tetrafibricin (A, Figure 2a).^[7]



Figure 1. Biologically active natural product structures with chiral 1,5,7-triol motifs.

With the 1,5-polyol stereochemical obstacle surmounted, we sought to expand this strategy in order to address 1,5,7-triol systems that appear in tetrafibricin and in a variety of other bioactive natural products (Figure 1) such as bastimolide A (antimalarial)^[10a] and marinomycin А (antitumor, antimicrobial).^[10b] We noted that two iterations of our polyol synthesis approach furnishes a 1,5,9-triol complemented by two alkene functionalities, and hypothesized that the alkenes might be engaged for the subsequent delivery of additional hydroxyl equivalents, expanding the repertoire of polyols accessible by our configuration-encoded approach. The feasibility of this would require selectively addressing a new oxygen substituent to a defined location, as implied in structures **B** and **C** (Figure 2b). The Evans tactic of benzylidene acetal construction, exploiting a free hydroxyl group to direct intramolecular conjugate addition to an unsaturated ester,^[11] appeared well-suited for this purpose. Here we present a successful test of this hypothesis en route to the anti,syn-1,5,7-triol which appears in the C15-C25 fragment of tetrafibricin.

COMMUNICATION

WILEY-VCH





A (1,5,9-triol, C27–C40 of tetrafibricin)

(b) This Study:



C (1,5,7-triol, C15–C25 of tetrafibricin)

Figure 2. a) Application of configuration-encoded 1,5-polyol synthesis to the C27–C40 fragment of tetrafibricin; b) New strategy to access 1,5,7-triols and application to the C15–C25 fragment of tetrafibricin.

Results and Discussion

In the plan for the 1,5,7-triol synthesis, two configurationencoded building blocks with differentiated hydroxyl groups were required. After 1,5-polyol assembly, this would permit selective deprotection and hydroxyl-directed benzylidene acetal construction upon an unsaturated ester (see structure B, Figure 2b). We opted for selective desilylation, exploiting the differential and reactivity of tert-butyldimethylsilyl (TBS) tertbutyldiphenylsilyl (TBDPS) groups. Preparation of the TBS building block 1 (Figure 2a) followed our earlier route (Scheme 1) from commercially available acrolein and 1-phenyl-1Htetrazol-5-thiol. This provided multigram quantities of enantiopure α -silyloxy- γ -sulfononitriles (R)-1 and (S)-1 in 87% and 89% yields respectively over 4 steps (>99% ee after recrystallization).[7]

For the building block with the hydroxyl group differentiated from that in **1**, we returned to cyanohydrin (R)-**2** (Scheme 1), prepared via catalytic asymmetric cyanohydrin construction en route to (R)-**1**. Silylation of cyanohydrin (R)-**2** with TBDPSCI, followed by molybdate-catalyzed oxidation of the sulfide to sulfone, smoothly furnished (R)-**3** as a waxy solid (94% ee, HPLC). The enantiomeric excess of (R)-**3** was generated during cyanohydrin construction without any enrichment through crystallization, and the 94% ee represents an improvement versus the prior report.^[12]



Scheme 1. Synthesis of α -Silyloxy- γ -Sulfononitrile Building Blocks



Scheme 2. Application of Iterative 1,5-Polyol Methodology to Carbon Skeleton of C15–C25 Fragment of Tetrafibricin

COMMUNICATION

WILEY-VCH



Scheme 3. Diastereoselective Conjugate Addition to Access the anti, syn-1,5,7-Triol of the C15-C25 Fragment of Tetrafibricin

With the enantiopure α -silyloxy- γ -sulfononitrile building blocks (S)-1 and (R)-3 in hand, we turned to assembly of the carbon skeleton of the C15-C25 fragment of tetrafibricin via configuration-encoded 1,5-polyol synthesis (Scheme 2). Julia-Kocienski coupling of protected glycolaldehyde 4^[13] with (S)-1 afforded olefin 5 in 86% yield (E/Z 90:10 after purification).[14,15] Nitrile reduction with DIBAL-H would reveal the aldehyde needed for the next iteration. Unexpectedly,^[16] the hydrolysis of the crude imine intermediate in this step was very sensitive to acid-catalyzed racemization, readily observable after the next coupling event.^[17] After extensive exploration, a dilute (0.1 mM) aqueous tartaric acid workup corrected this problem. Prompt Julia-Kocienski coupling of the crude aldehyde with building block (R)-3 gave anti-1,5-diol 6 in 52% yield over 2 steps with excellent stereocontrol (E,E/Z,E >95:5, 19S/19R 97:3).[18] The DIBAL-H reduction of nitrile 6 behaved normally during workup, with no detected epimerization, and methylenation of the resulting α -silvloxy aldehyde with 5-(methylsulfonyl)-1-phenyl-1H-tetrazole (MeSO₂PT)^[19] under Julia-Kocienski conditions furnished 1,5,9-triol 7 with an 83% yield over 2 steps (23R/23S >95:5).[20]

Next, with the C15-C25 carbon framework and anti-1,5-diol stereochemistry established, attention turned to delivering the remaining hydroxyl equivalent to complete the targeted anti-syn-1,5,7-triol moiety (Scheme 3). Oxidative hydrolysis of PMB ether 7 and oxidation of the resulting allylic alcohol (8) under Corey's conditions provided methyl ester 9 (80% yield).^[21] Selective desilylation of the TBS ether with HCI (10, 96% yield) then set the stage for the Evans tactic of benzylidene acetal construction via intramolecular conjugate addition. Using a portionwise addition of benzaldehyde and KHMDS with warming between additions, construction of acetal 11 proceeded in 63% yield with excellent diastereoselectivity at the syn-1,3-diol moiety (syn/anti >95:5) and 15% recovery of unreacted alcohol 10.[22] The syn-1,3 configuration was confirmed by two large vicinal coupling constants observed for the axial proton at C18 ($J_{geminal}$ = 13.1 Hz, $J_{vicinal}$ = 11.3, 11.3 Hz), consistent with precedent for similar compounds.23

Lastly, having the anti,syn-1,5,7-triol stereochemistry secured, adjustment of C25 functionality of the terminal olefin 11 would facilitate future fragment coupling studies. Selective hydroboration (9-BBN, then H₂O₂ and NaOAc) furnished a primary alcohol (12) in 68% yield with 7% recovery of unreacted olefin. Finally, Swern oxidation (85% yield) gave aldehyde 13, having terminal functionality suitable for fragment coupling efforts. This C15-C25 fragment is endowed with all the stereochemical features needed for synthesis of tetrafibricin.

Conclusions

A new strategy to access anti, syn-1,5,7-triols has been designed and executed in the context of tetrafibricin, a fibrinogen receptor antagonist. Iterative configuration-encoded synthesis of chiral 1,5-polyols was merged with diastereoselective intramolecular conjugate addition, providing the anti,syn-1,5,7triol subunit of tetrafibricin with excellent stereocontrol. Fragment coupling studies and further efforts toward the total synthesis of tetrafibricin will be reported in due course.

Acknowledgements

We thank the University of Iowa for support, including a Graduate College Fellowship to RMF and a Ralph Shriner Graduate Fellowship to RMF.

Keywords: natural products • asymmetric synthesis • olefination alcohols

Isolation, structure, and biological activity: a) T. Kamiyama, T. Umino, N. [1] Fujisaki, K. Fujimori, T. Satoh, Y. Yamashita, S. Ohshima, J. Watanabe K. Yokose, J. Antibiot. 1993, 46, 1039; b) T. Kamiyama, Y. Itezono, T. Umino, T. Satoh, N. Nakayama, K. Yokose, J. Antibiot. 1993, 46, 1047; c) T. Satoh, Y. Yamashita, T. Kamiyama, J. Watanabe, B. Steiner, P. Hadvary, M. Arisawa, Thromb. Res. 1993, 72, 389; d) T. Satoh, Y. Yamashita, T. Kamiyama, M. Arisawa, Thromb. Res. 1993, 72, 401; e) T. Satoh, W. C. Kouns, Y. Yamashita, T. Kamiyama, B. Steiner, Biochem. J. 1994, 301, 785; f) T. Satoh, W. C. Kouns, Y. Yamashita, T. Kamiyama, B. Steiner, Biochem. Biophys. Res. Commun. 1994, 204, 325

Y. Kobayashi, W. Czechtizky, Y. Kishi, Org. Lett. 2003, 5, 93.

[2] S. BouzBouz, J. Cossy, Org. Lett. 2004, 6, 3469. [3]

- [4] a) V. Gudipati, D. P. Curran, *Tetrahedron Lett.* 2011, *52*, 2254; b) K.
 Zhang, V. Gudipati, D. P. Curran, *Synlett* 2010, 667; c) V. Gudipati, R.
 BajPai, D. P. Curran, *Collect. Czech. Chem. Commun.* 2009, *74*, 771; d) K. Zhang, *Ph.D. Thesis*, University of Pittsburgh, 2011.
- [5] a) T. Itoh, T. P. Montgomery, A. Recio III, M. J. Krische, *Org. Lett.* 2014, *16*, 820; b) E. T. T. Kumpulainen, B. Kang, M. J. Krische, *Org. Lett.* 2011, *13*, 2484.
- [6] a) P. Nuhant, W. R. Roush, *J. Am. Chem. Soc.* 2013, 135, 5340; b) J. Kister, P. Nuhant, R. Lira, A. Sorg, W. R. Roush, *Org. Lett.* 2011, 13, 1868; c) P. Nuhant, J. Kister, R. Lira, A. Sorg, W. R. Roush, *Tetrahedron* 2011, 67, 6497; d) R. Lira, W. R. Roush, *Org. Lett.* 2007, 9, 533.
- [7] G. K. Friestad, G. Sreenilayam, Org. Lett. 2010, 12, 5016.
- [8] a) Review of 1,5-polyols: G. K. Friestad, G. Sreenilayam, *Pure Appl. Chem.* 2011, *83*, 461. Also see: (b) Y. Yang, G. He, R. Yin, L. Zhu, X. Wang, R. Hong, *Angew. Chem. Int. Ed.* 2014, *53*, 11600; c) P. R. Hanson, S. Jayasinghe, S. Maitra, C. N. Ndi, R. Chegondi, *Beilstein J. Org. Chem.* 2014, *10*, 2332; d) D. De Joarder, M. P. Jennings, *Tetrahedron Lett.* 2013, *54*, 5826; e) P. Sawant, M. E. Maier, *Synlett* 2011, 3002; f) R. Matsui, K. Seto, Y. Sato, T. Suzuki, A. Nakazaki, S. Kobayashi, *Angew. Chem. Int. Ed.* 2011, *50*, 680.
- [9] Review: S. E. Bode, M. Wolberg, M. Muller, Synthesis 2006, 557.
- a) C.-L. Shao, R. G. Linington, M. J. Balunas, A. Centeno, P. Boudreau,
 C. Zhang, N. Engene, C. Spadafora, T. S. Mutka, D. E. Kyle, L. Gerwick, C.-Y. Wang, W. H. Gerwick, *J. Org. Chem.* 2015, *80*, 7849; b)
 H. C. Kwon, C. A. Kauffman, P. R. Jensen, W. Fenical, *J. Am. Chem. Soc.* 2006, *128*, 1622.
- [11] D. A. Evans, J. A. Gauchet-Prunet, J. Org. Chem. 1993, 58, 2446.
- [12] a) Asymmetric cyanation to form (*R*)-2 in the prior report (ref. 7) was of slightly lower selectivity (83–86%ee). The improvement noted herein may be attributed to better temperature control via slow addition, and to differences in the amount of HCN present in the TMSCN reagent. For precedent, see F. Yang, S. Wei, P. Xi, L. Yang, J. Lan, J. You, C. A.

Chen, H. M. Gau, *Chem. Eur. J.* **2008**, *14*, 2223; b) Enantiomerically pure (*R*)-**3** was obtained by recrystallization of (*R*)-**1**, desilylation under acidic conditions (TsOH, MeOH), and silylation with TBDPSCI and imidazole (see Supporting Information).

- [13] R. Chenevert, M. Dasser, J. Org. Chem. 2000, 65, 4529.
- [14] Review: P. R. Blakemore, J. Chem. Soc., Perkin Trans. 1 2002, 2563.
- [15] a) The combination of KHMDS and THF afforded lower selectivity (*E/Z* 78:22); b) The *E/Z* ratios were measured by ¹H NMR integrations before and after purification and confirmed by GC-HRMS (see Supporting Information); c) These *E/Z* isomers were not easily separable, but anticipating saturation later in the sequence, the reaction was not optimized further.
- [16] Retention of configuration in α-silyloxy aldehydes: (a) M. Hayashi, T. Yoshiga, K. Nakatani, K. Ono, N. Oguni, *Tetrahedron* 1994, *50*, 2821;
 b) D. Enders, A. Plant, D. Backhaus, U. Reinhold, *Tetrahedron* 1995, *51*, 10699; c) Also see ref. 7.
- [17] Diastereomers were evident in ¹H and ¹³C NMR spectra after the next Julia–Kocienski coupling (see Supporting Information).
- [18] Isomer ratios were measured by ¹H NMR integrations. No minor (*Z*,*E*)or (*Z*,*Z*)-isomers were observed in ¹H and ¹³C NMR spectra.
- [19] N. Toda, S. Asano, C. F. Barbas III, Angew. Chem. Int. Ed. 2013, 52, 12592.
- [20] No (S,S)-diastereomer peaks were observed by ¹H and ¹³C NMR.
- [21] E. J. Corey, N. W. Gilman, B. E. Ganem, J. Am. Chem. Soc. 1968, 90, 5616.
- a) See ref. 11; b) When KOt-Bu used as the base instead of KHMDS, the product formed in 17% yield with 58% recovered starting material;
 c) No evidence of *anti*-1,3 diastereomer was observed in ¹H and ¹³C NMR spectra.
- [23] a) Peak assignments confirmed by ¹H–¹H COSY NMR; b) See ref. 11.

COMMUNICATION

WILEY-VCH

Entry for the Table of Contents (Please choose one layout)

COMMUNICATION

